EP1845099A4 - Artemisin- (qinghaosu-) derivate, verfahren zu deren herstellung und deren verwendung, und diese enthaltende pharmazeutische zusammensetzungen - Google Patents

Artemisin- (qinghaosu-) derivate, verfahren zu deren herstellung und deren verwendung, und diese enthaltende pharmazeutische zusammensetzungen

Info

Publication number
EP1845099A4
EP1845099A4 EP06705603A EP06705603A EP1845099A4 EP 1845099 A4 EP1845099 A4 EP 1845099A4 EP 06705603 A EP06705603 A EP 06705603A EP 06705603 A EP06705603 A EP 06705603A EP 1845099 A4 EP1845099 A4 EP 1845099A4
Authority
EP
European Patent Office
Prior art keywords
artemisine
qinghaosu
derivatives
pharmaceutical compositions
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06705603A
Other languages
English (en)
French (fr)
Other versions
EP1845099A1 (de
EP1845099B1 (de
Inventor
Ying Li
Jianping Zuo
Zhongshun Yang
Wenliang Zhou
Yi Sui
Junxia Wang
Yu Zhang
Yu Zhou
Jinming Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of EP1845099A1 publication Critical patent/EP1845099A1/de
Publication of EP1845099A4 publication Critical patent/EP1845099A4/de
Application granted granted Critical
Publication of EP1845099B1 publication Critical patent/EP1845099B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP06705603A 2005-02-04 2006-01-27 Artemisin- (qinghaosu-) derivate, verfahren zu deren herstellung und deren verwendung, und diese enthaltende pharmazeutische zusammensetzungen Active EP1845099B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA2005100238241A CN1814601A (zh) 2005-02-04 2005-02-04 具有免疫抑制作用的青蒿素衍生物及药物组合物
PCT/CN2006/000182 WO2006081771A1 (fr) 2005-02-04 2006-01-27 Dérivés d'artémisine (qinghaosu), méthodes de synthèse et applications, et préparations pharmaceutiques contenant lesdits dérivés

Publications (3)

Publication Number Publication Date
EP1845099A1 EP1845099A1 (de) 2007-10-17
EP1845099A4 true EP1845099A4 (de) 2010-10-06
EP1845099B1 EP1845099B1 (de) 2012-10-24

Family

ID=36776974

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06705603A Active EP1845099B1 (de) 2005-02-04 2006-01-27 Artemisin- (qinghaosu-) derivate, verfahren zu deren herstellung und deren verwendung, und diese enthaltende pharmazeutische zusammensetzungen

Country Status (5)

Country Link
US (1) US7910750B2 (de)
EP (1) EP1845099B1 (de)
JP (1) JP4891926B2 (de)
CN (2) CN1814601A (de)
WO (1) WO2006081771A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102010420B (zh) * 2010-10-12 2013-11-27 沈阳药科大学 [(10s)-9,10-二氢青蒿素-10-氧基]苯甲醛缩氨基(硫)脲系列物及其制备方法和用途
EP3269371A1 (de) 2011-06-10 2018-01-17 Queen Mary University of London Artemisinin und dessen derivate zur behandlung von myokardininfarkten oder der koronaren kerzkrankheit
WO2013130725A1 (en) * 2012-02-28 2013-09-06 The Johns Hopkins University Trioxane thioacetal monomers and dimers and methods of use thereof
CN102603768A (zh) * 2012-03-07 2012-07-25 广州牌牌生物科技有限公司 一种使用大孔树脂分离纯化青蒿素的方法
US9663532B2 (en) 2012-10-29 2017-05-30 University Of Rochester Artemisinin derivatives, methods for their preparation and their use as antimalarial agents
EP2931283B1 (de) 2012-12-12 2020-04-08 Queen Mary and Westfield College University of London Artemisinin und dessen derivate zur verwendung bei der behandlung von nierenerkrankungen
US20170326102A1 (en) * 2014-11-27 2017-11-16 Cipla Limited Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery
CN108653272B (zh) * 2017-03-31 2022-09-20 中国科学院上海药物研究所 青蒿素类衍生物在制备用于治疗炎症性肠病的药物中的用途
WO2021186396A2 (en) * 2020-03-18 2021-09-23 Oncotelic Inc. Tgf-beta inhibition, agents and composition therefor
CN115068478B (zh) * 2022-07-22 2024-01-09 上海医药工业有限公司 磷酸萘酚喹在制备治疗自身免疫性疾病药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390840A (zh) * 2001-06-08 2003-01-15 中国科学院上海药物研究所 青蒿素芳香醚类衍生物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791135A (en) 1987-08-20 1988-12-13 The United States Of America As Represented By The Secretary Of The Army Novel antimalarial dihydroartemisinin derivatives
CN1038416C (zh) * 1992-12-04 1998-05-20 中国科学院上海药物研究所 新型青蒿素衍生物及其制备方法
CN1049435C (zh) * 1994-11-09 2000-02-16 中国科学院上海药物研究所 含苯基和杂环基的青蒿素衍生物及其制备方法
EP1040836A4 (de) * 1997-12-24 2004-11-10 Fujisawa Pharmaceutical Co Immunsuppressive agonisten
CN1109035C (zh) * 1998-04-08 2003-05-21 中国科学院上海药物研究所 12位芳基取代的青蒿素衍生物、制备方法及其应用
CN1084333C (zh) 1998-06-17 2002-05-08 中国科学院上海药物研究所 新的青蒿素化合物,其制备方法以及含有它们的药物组合物
IN191696B (de) * 1999-02-12 2003-12-20 Council Scient Ind Res
EP1465899A1 (de) * 2001-12-06 2004-10-13 Ufc Limited Trioxan derivate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390840A (zh) * 2001-06-08 2003-01-15 中国科学院上海药物研究所 青蒿素芳香醚类衍生物及其制备方法

Also Published As

Publication number Publication date
JP4891926B2 (ja) 2012-03-07
EP1845099A1 (de) 2007-10-17
US7910750B2 (en) 2011-03-22
WO2006081771A1 (fr) 2006-08-10
CN101103036A (zh) 2008-01-09
US20080139642A1 (en) 2008-06-12
CN1814601A (zh) 2006-08-09
EP1845099B1 (de) 2012-10-24
CN101103036B (zh) 2010-05-19
JP2008528641A (ja) 2008-07-31

Similar Documents

Publication Publication Date Title
IL188050A (en) The history of azaindazole, their medicinal preparations and their uses
IL189737A0 (en) Pyrazine derivatives, their preparation and pharmaceutical compositions containing them
IL188941A0 (en) Pyrazinolyguanidine derivatives and pharmaceutical compositions containing the same
IL186738A0 (en) Pyrizole derivatives and pharmaceutical compositions containing the same
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
IL185353A0 (en) Azabicycloalkane derivatives , pharmaceutical compositions containing the same and methods for the preparation thereof
IL183919A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
IL189782A0 (en) Sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
IL184783A0 (en) Aminopyridine derivatives and pharmaceutical compositions containing the same
IL193240A0 (en) Dihydrodiazepine derivatives and pharmaceutical compositions containing the same
IL177533A (en) Benzimidazole derivatives, their preparation and pharmaceutical compositions comprising them
IL173195A0 (en) Cyclovinylazoline derivatives, their preparation and pharmaceutical compositions containing them
IL177168A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
IL190292A (en) History of pyridopyrimidinone and their pharmaceutical preparations
IL187224A0 (en) Bicyclic derivatives and pharmaceutical compositions containing the same
EP1841761A4 (de) Fumagillolderivate oder verfahren zur herstellung von fumagillolderivaten, und pharmazeutische zusammensetzungen, die diese enthalten
IL221323A0 (en) 1-methyl-1h- pyridin-2-one- phenanthridine derivatives and pharmaceutical compositions containing the same
IL187391A0 (en) Thiazole derivatives, their preparation and use and pharmaceutical compositions containing them
EP1845099A4 (de) Artemisin- (qinghaosu-) derivate, verfahren zu deren herstellung und deren verwendung, und diese enthaltende pharmazeutische zusammensetzungen
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
EP1911761A4 (de) Wasserlösliche artemisininderivate, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen und ihre verwendung
EP1961753A4 (de) Pyrazolopyrimidinonderivate, ihre herstellung und ihre verwendung
EP1916251A4 (de) Erianinsalze, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten
IL184996A0 (en) Dihydroimidazothiazole derivatives and pharmaceutical compositions containing the same
HUP0401522A2 (en) New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070803

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100906

17Q First examination report despatched

Effective date: 20110829

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZHOU, YU

Inventor name: LI, YING

Inventor name: WANG, JUNXIA

Inventor name: SUI, YI

Inventor name: ZHANG, YU

Inventor name: ZHOU, WENLIANG

Inventor name: ZUO, JIANPING

Inventor name: WU, JINMING

Inventor name: YANG, ZHONGSHUN

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006032617

Country of ref document: DE

Owner name: JIANGSU ZUOYOU MEDICINE CO., LTD., CN

Free format text: FORMER OWNER: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SHANGHAI, CN

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 580882

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006032617

Country of ref document: DE

Effective date: 20121220

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 580882

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121024

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20121024

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130224

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130225

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130125

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130124

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130131

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20130725

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130204

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130131

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006032617

Country of ref document: DE

Effective date: 20130725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121024

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130127

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060127

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006032617

Country of ref document: DE

Representative=s name: GRUENECKER PATENT- UND RECHTSANWAELTE PARTG MB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006032617

Country of ref document: DE

Owner name: JIANGSU ZUOYOU MEDICINE CO., LTD., CN

Free format text: FORMER OWNER: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SHANGHAI, CN

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20160310 AND 20160316

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: JIANGSU ZUOYOU MEDICINE, CN

Effective date: 20160413

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231226

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240124

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240129

Year of fee payment: 19

Ref country code: FR

Payment date: 20240126

Year of fee payment: 19